pubmed-article:7514434 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C0038250 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C0229664 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C0218640 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C0040223 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C0332152 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C1261322 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C0036576 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C1879533 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C1521721 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C0205289 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
pubmed-article:7514434 | lifeskim:mentions | umls-concept:C2698651 | lld:lifeskim |
pubmed-article:7514434 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:7514434 | pubmed:dateCreated | 1994-6-23 | lld:pubmed |
pubmed-article:7514434 | pubmed:abstractText | In advanced breast cancer high-dose consolidation chemotherapy with haematological rescue has resulted in prolonged disease free and overall survival in a small percentage of patients. Maximal reduction of the tumor burden by intensive induction treatment preceding the high-dose chemotherapy may favor that outcome. The aims of this study were to find a rapid highly effective induction regimen with acceptable toxicity and to examine the optimal time for peripheral blood progenitor cell (PBPC) collection for haematological rescue. | lld:pubmed |
pubmed-article:7514434 | pubmed:language | eng | lld:pubmed |
pubmed-article:7514434 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7514434 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:7514434 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7514434 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7514434 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7514434 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7514434 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7514434 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7514434 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:7514434 | pubmed:month | Mar | lld:pubmed |
pubmed-article:7514434 | pubmed:issn | 0923-7534 | lld:pubmed |
pubmed-article:7514434 | pubmed:author | pubmed-author:DexterT MTM | lld:pubmed |
pubmed-article:7514434 | pubmed:author | pubmed-author:BaumannII | lld:pubmed |
pubmed-article:7514434 | pubmed:author | pubmed-author:TestaN GNG | lld:pubmed |
pubmed-article:7514434 | pubmed:author | pubmed-author:LangeCC | lld:pubmed |
pubmed-article:7514434 | pubmed:author | pubmed-author:RansonMM | lld:pubmed |
pubmed-article:7514434 | pubmed:author | pubmed-author:Van HoefM EME | lld:pubmed |
pubmed-article:7514434 | pubmed:author | pubmed-author:LuffJJ | lld:pubmed |
pubmed-article:7514434 | pubmed:author | pubmed-author:MorgensternG... | lld:pubmed |
pubmed-article:7514434 | pubmed:author | pubmed-author:YvertBB | lld:pubmed |
pubmed-article:7514434 | pubmed:author | pubmed-author:de WynterE... | lld:pubmed |
pubmed-article:7514434 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:7514434 | pubmed:volume | 5 | lld:pubmed |
pubmed-article:7514434 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:7514434 | pubmed:authorsComplete | N | lld:pubmed |
pubmed-article:7514434 | pubmed:pagination | 217-24 | lld:pubmed |
pubmed-article:7514434 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:meshHeading | pubmed-meshheading:7514434-... | lld:pubmed |
pubmed-article:7514434 | pubmed:year | 1994 | lld:pubmed |
pubmed-article:7514434 | pubmed:articleTitle | Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal time to collect peripheral blood progenitor cells for haematological rescue after high-dose consolidation chemotherapy. | lld:pubmed |
pubmed-article:7514434 | pubmed:affiliation | CRC Dept. of Medical Oncology, Christie Hospital, Manchester U.K. | lld:pubmed |
pubmed-article:7514434 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:7514434 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:7514434 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:7514434 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7514434 | lld:pubmed |